HF/Transplantation News

Breast cancer survivors who developed incident myocardial infarction or heart failure exhibited increased risk for adverse oncologic outcomes, according to a population-based cohort study.

Regardless of country-level income classification, medications for the secondary prevention of CVD remains underutilized and patients likely remain undertreated, researcher reported.

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications consumed more than 80% of Medicare Part D spending, researchers reported.

Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related cardiac events than those treated with other EGFR tyrosine kinase inhibitors.

Black individuals in the U.S. with serious illnesses receive disproportionately poor pain management and health care communication, compared with white individuals, a focus group led by the Center to Advance Palliative Care showed.

The American Heart Association has issued the 2025 update to its annual heart disease and stroke statistics report, detailing recent trends in CV-related morbidity and mortality.

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March 29-31 in Chicago and online.

Increased intermuscular fat, not BMI, was independently associated with coronary microvascular function and major adverse CV events, according to new data published in the European Heart Journal.

Recent changes to a heart transplant allocation policy improved waitlist outcomes for children born with heart defects and adults with cardiomyopathy, but not in children with cardiomyopathy or adults with heart defects, data show.